Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI)

Vaccine

Volumn 29, Issue 31, 2011, Pages 4897-4902

  Taylor, David N ^a   Treanor, John J ^b   Strout, Cynthia ^c   Johnson, Casey ^d   Fitzgerald, Theresa ^b   Kavita, Uma ^a   Ozer, Karen ^e   Tussey, Lynda ^a   Shaw, Alan ^a  

^a VaxInnate Corporation   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c Coastal Carolina Research Center ^*  (United States)

^d Johnson County Clin Trials   (United States)

^e Cytel Incorporated   (United States)

Author keywords

Elderly; Flagellin; Influenza; Recombinant; Toll like receptor 5; Vaccine

Indexed keywords

ANTIBODY; C REACTIVE PROTEIN; FLAGELLIN; FLAGELLIN ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT HEMAGGLUTININ INFLUENZA FLAGELLIN FUSION VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VAX 125;

AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; ECCHYMOSIS; ESCHERICHIA COLI; FATIGUE; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; SIDE EFFECT; SWEATING;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ESCHERICHIA COLI; FEMALE; FLAGELLIN; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; RECOMBINANT FUSION PROTEINS; TOLL-LIKE RECEPTOR 5; VACCINES, SYNTHETIC;

EID: 79959736816     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.001     Document Type: Article

References (22)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
2. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
3. Poland G.A., Mulligan M.J. The imperative of influenza vaccines for elderly individuals-an evolving story. J Infect Dis 2009, 200:161-163.
4. Demicheli V., Rivetti D., Deeks J.J., Jefferson T.O. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004, (3):CD001269. [Review. Update in: Cochrane Database Syst Rev 2007;(2):CD00126].
5. Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., Strikas R.A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-42.
6. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007, 10:658-666.
7. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind, controlled Phase 3 trial comparing immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200:172-180.
8. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19:2673-2680.
9. Hebert D.N., Zhang J.X., Chen W., Foellmer B., Helenius A. The number and location of glycans on influenza hemagglutinin determine folding and association with calnexin and calreticulin. J Cell Biol 1997, 139:613-623.
10. Klenk H.D., Wagner R., Heuer D., Wolff T. Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res 2002, 82:73-75.
11. Bright R.A., Ross T.M., Subbarao K., Robinson H.L., Katz J.M. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 2003, 308:270-278.
12. Treanor J.J., Taylor D.N., Tussey L., Hay C., Nolan C., Fitzgerald T., et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010, 28:8268-8274.
13. Dowdle W.N., Kendal A.P., Noble G.R. Influenza viruses. Diagnostic procedures for viral, rickettsial, and chlamydial infections 1979, 603-605. American Public Health Association, Washington (DC). 5th ed. E.H. Lenette, N.J. Schmidt (Eds.).
14. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808-812.
15. Blander J.M., Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004, 304:1014-1018.
16. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25:763-775.
17. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
18. Panda A., Qian F., Mohanty S., van Duin D., Newman F.K., Zhang L., et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010, 184:2518-2527.
19. Song L., Nakaar V., Kavita U., Price A., Huleatt J., Tang J., et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 2008, 3:e2257.
20. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24:1159-1169.
21. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 2010, 10:18.
22. Barrett P.N., Berezuk G., Fritsch S., Aichinger G., Hart M.K., El-Amin W., et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377(9767):751-759.